Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 33: 1652-1655, 1987;
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hursting, M. J.
Right arrow Articles by Smith, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hursting, M. J.
Right arrow Articles by Smith, T. W.

Clinical Chemistry, Vol 33, 1652-1655, Copyright © 1987 by American Association for Clinical Chemistry

Determination of free digoxin concentrations in serum for monitoring Fab treatment of digoxin overdose

MJ Hursting, VA Raisys, KE Opheim, JL Bell, GB Trobaugh and TW Smith

A rapid method for assessing the free digoxin concentration in the serum of digoxin-overdosed patients receiving treatment with digoxin- specific Fab fragments has been developed. For this method, a protein- free ultrafiltrate is prepared from the patient's serum, and the digoxin in the ultrafiltrate (free digoxin) is measured by fluorescence polarization immunoassay. Both the inaccuracies associated with measurements of total digoxin by immunoassay in the presence of Fab and the long turnaround time associated with measurements of free digoxin by equilibrium dialysis were avoided. Good correlation was observed between measurements of free digoxin by this ultrafiltration technique and by equilibrium dialysis. The ultrafiltration method was used to evaluate the concentrations of free digoxin in a digoxin-overdosed patient treated with Fab at our hospital. In retrospect, the results suggest that her hospital stay could have been shortened by a timely appreciation of her increased concentration of free digoxin. Using the ultrafiltration method, one can determine free digoxin concentrations quickly, conveniently, and accurately in the clinical laboratory. This procedure therefore should be a valuable aid in monitoring the efficacy and adequacy of Fab treatment.


The following articles in journals at HighWire Press have cited this article:


Home page
 QJMHome page
R. Sharma, M. Guy, A. Rudenski, E. Lamerton, and P.A. Kalra
The limitations of routine total digoxin immunoassay in patients with advanced chronic kidney disease
QJM, October 1, 2009; 102(10): 747 - 750.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. A. McMillin, W. E. Owen, T. L. Lambert, B. K. De, E. L. Frank, P. R. Bach, T. M. Annesley, and W. L. Roberts
Comparable Effects of DIGIBIND and DigiFab in Thirteen Digoxin Immunoassays
Clin. Chem., September 1, 2002; 48(9): 1580 - 1584.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. Rainey, I. T. Ocal, and T. R. Green
Digibind and Free Digoxin • The authors of the article cited above respond:
Clin. Chem., May 1, 1999; 45(5): 719 - 721.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. Valdes Jr. and S. A. Jortani
Monitoring of Unbound Digoxin in Patients Treated with Anti-Digoxin Antigen-binding Fragments: A Model for the Future?
Clin. Chem., September 1, 1998; 44(9): 1883 - 1885.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
I. T. Ocal and T. R. Green
Serum digoxin in the presence of Digibind: determination of digoxin by the Abbott AxSYM and Baxter Stratus II immunoassays by direct analysis without pretreatment of serum samples
Clin. Chem., September 1, 1998; 44(9): 1947 - 1950.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by the American Association for Clinical Chemistry.